Acrivon Therapeutics' Precision Medicine Advancements

Acrivon Therapeutics, a clinical stage biopharmaceutical company, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company's CEO will participate in a fireside chat, showcasing its precision oncology medicines using the AP3 platform. Acrivon's lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2 in a Phase 2 trial across multiple tumor types. The company has received Fast Track designation and Breakthrough Device designation from the FDA for ACR-368 and its OncoSignature assay, respectively. Acrivon is also developing preclinical stage pipeline programs, such as ACR-2316 and an undisclosed cell cycle program.